Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

This study tests a new approach for people with advanced HPV16-related cancers that have come back or spread. Participants receive immune cells from a family donor to help fight the cancer. The goal is to see if this treatment is safe and can boost the body's immune response agai…

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery, shown by rising PSA levels. The goal is to see if olaparib can lower PSA by at least 50% and delay further progression. Participants must have had their prostate removed and have a shor…

This study enrolls healthy relatives of patients with advanced HPV-related head and neck cancer. Donors receive a therapeutic HPV vaccine to boost their immune cells against HPV. These cells are then collected and used in a separate transplant or cell infusion to treat the patien…

This study tested a combination of drugs (avelumab, palbociclib, and hormone therapy) given before surgery to people with early-stage, hormone-sensitive breast cancer. The goal was to see if the treatment could shrink or eliminate tumors. 33 participants received the drugs for ab…

This early-phase study tests a new oral drug combination (E7727 plus decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and to see if the drugs can slow tumor growth. Up to 35 parti…

This study tests two immunotherapy drugs, nivolumab and urelumab, given before bladder removal surgery for patients with muscle-invasive bladder cancer who cannot or choose not to have chemotherapy. The goal is to see if adding urelumab boosts the immune response against the tumo…

This early-stage study tests the safety of combining an immunotherapy drug (nivolumab) with or without precise radiation (stereotactic radiosurgery) in 21 people with chordoma that has returned or spread. The goal is to see if this combination is safe and tolerable. Participants …

This study tested whether adding the drug vorinostat to standard chemotherapy (carboplatin and nab-paclitaxel) before surgery could improve outcomes for women with HER2-negative breast cancer. About 68 participants received either the chemo combo with vorinostat or a placebo. The…

This study tests a combination of two drugs, nivolumab and relatlimab, in people with advanced solid tumors that have a specific genetic feature (MSI-H) and have stopped responding to previous immunotherapy. The goal is to see if this new combination can shrink tumors or slow the…

This early-phase trial tests whether giving immunotherapy drugs (nivolumab or nivolumab/relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. The goal is to see if this approach can ch…

This study looks at whether continuing the drug palbociclib but switching to a different hormone therapy (fulvestrant) can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to palbociclib and an aromatase inhibitor.…

This study was designed to test whether giving a KRAS G12C-targeted drug (adagrasib) alone or with an immunotherapy (nivolumab) before surgery could improve outcomes for people with a specific type of non-small cell lung cancer. It was planned for adults with resectable tumors an…

This early-phase study tests a vaccine targeting mutant KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in patients with colorectal or pancreatic cancer that has been surgically removed. The goal is to see if the combination is safe and boosts the…

This study is testing different combinations of immunotherapy drugs given before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if these treatments can boost the immune system to fight the cancer better. About 76 participants will be e…

This study tests whether giving a higher radiation dose to a specific brain area (the subventricular zone) during standard treatment can delay tumor regrowth in people with newly diagnosed glioblastoma. About 60 participants will receive either the modified radiation plus standar…

This study tests a combination of three drugs (paclitaxel, pembrolizumab, and olaparib) in people with advanced stomach or gastroesophageal cancer that has worsened after one prior treatment. The goal is to see if this mix is safe and helps patients live longer. About 36 adults w…

This study tests whether giving two immunotherapy drugs together before surgery is safe and practical for people with head and neck cancer. The drugs aim to boost the immune system to fight the tumor. About 24 participants will receive the treatment before their planned surgery, …

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) before surgery to people with early-stage non-small cell lung cancer. The goal was to see if it is safe and can shrink tumors before removal. 39 participants received treatment, and researchers look…

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This early-stage study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before and after surgery is safe and helps patients with liver cancer that can be removed. About 31 adults with resectable liver cancer will receive the drugs, then undergo surger…

This early-phase study tests whether the drug itacitinib can prevent a serious complication called cytokine release syndrome (CRS) after a stem cell transplant in people aged 60 and older with blood cancers. The study involves 32 participants who receive a 'mini' transplant from …

This study tests whether adding targeted radiation to the immunotherapy drug nivolumab (alone or with another drug, relatlimab) can help control advanced stomach, esophageal, or gastroesophageal junction cancer. About 21 adults with limited metastatic disease will receive radiati…

This study tests a combination of two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder for people with early-stage bladder cancer who have not received standard BCG therapy. The goal is to see if this treatment can clear the cancer and keep it from c…

This early-stage trial is testing whether combining two immunotherapy drugs with a precise, high-dose radiation treatment is safe and might help control recurrent glioblastoma, a very aggressive brain cancer. The study involves about 16 patients whose cancer has returned after in…

This study tests a special PET scan (18F-DCFPyL) that targets prostate cancer cells to see if it can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 who have not had a prior prostate biopsy will receive the scan before…

This early-phase study tests a new type of proton therapy called ProGRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can be delivered successfully. About 11 adults with sarcoma or melanoma are taking part.

This study explores whether advanced MRI techniques can detect early changes in prostate cancer and surrounding tissues during radiation therapy. By monitoring these changes, doctors hope to adjust treatment to reduce side effects and improve outcomes. The study involves 38 men w…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to bank these samples for future research on how radiation affects the prostate. However, the study was withdrawn before enrolling any participants, so no data …